{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:36:23Z","timestamp":1777700183083,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"vor","delay-in-days":387,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jcin.2016.02.013","type":"journal-article","created":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T18:15:58Z","timestamp":1463422558000},"page":"1036-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Optimal P2Y 12 Inhibitor in Patients With\u00a0ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"9","author":[{"given":"Asim M.","family":"Rafique","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Baber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Tobis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Currier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi H.","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2016.02.013_bib1","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","article-title":"Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry","volume":"113","author":"Spertus","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2016.02.013_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","article-title":"Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment","volume":"116","author":"Airoldi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2016.02.013_bib3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jacc.2009.03.083","article-title":"Antithrombotics in acute coronary syndromes","volume":"54","author":"Bonaca","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib4","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2016.02.013_bib6","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jacc.2011.06.044","article-title":"Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI randomized study","volume":"58","author":"Patti","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib8","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2016.02.013_bib9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2016.02.013_bib10","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2016.02.013_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction, Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcin.2016.02.013_bib12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jcin.2016.02.013_bib13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1253\/circj.CJ-11-0077","article-title":"Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. Impact on intracoronary thrombus burden and myocardial perfusion","volume":"75","author":"Vavuranakis","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jcin.2016.02.013_bib14","unstructured":"FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabloizers of the drug. March 12, 2010. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203888.htm. Accessed May 21,\u00a02015."},{"key":"10.1016\/j.jcin.2016.02.013_bib15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jacc.2007.12.013","article-title":"Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study","volume":"51","author":"L'Allier","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2016.02.013_bib17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.amjcard.2014.12.029","article-title":"Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity","volume":"115","author":"Lhermusier","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2016.02.013_bib19","doi-asserted-by":"crossref","first-page":"e92078","DOI":"10.1371\/journal.pone.0092078","article-title":"A\u00a0comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study","volume":"9","author":"Hibbert","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcin.2016.02.013_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","article-title":"Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study","volume":"60","author":"Alexopoulos","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2010.02.072","article-title":"Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP study","volume":"56","author":"Angiolillo","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib22","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib23","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A\u00a0randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI study","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib24","unstructured":"Marciniak T. FDA Advisory Committee for Ticagrelor. Ticagrelor for acute coronary syndromes, NDA 22\u2013433, changes from original version to amended version. July 28, 2010. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM220193.pdf. Accessed May 21,\u00a02015."},{"key":"10.1016\/j.jcin.2016.02.013_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2016.02.013_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ahj.2014.03.011","article-title":"Comparison of double ticagrelor loading dose with standard prasugrel loading dose in ST-elevation myocardial infarction patients: the RAPID primary PCI 2 study","volume":"167","author":"Parodi","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2016.02.013_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijcard.2013.04.149","article-title":"Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports","volume":"168","author":"Dinicolantonio","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2016.02.013_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000346151","article-title":"Exploring the ticagrelor-statin interplay in the PLATO trial","volume":"124","author":"Dinicolantonio","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.jcin.2016.02.013_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2015.05.062","article-title":"Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30day mortality in patients with ST-elevated myocardial infarction","volume":"195","author":"Serebruany","year":"2015","journal-title":"Int J Cardiol"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879816002570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879816002570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:55:44Z","timestamp":1536713744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879816002570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1936879816002570"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2016.02.013","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal P2Y12 Inhibitor in Patients With\u00a0ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2016.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American College of Cardiology Foundation. Published by Elsevier","name":"copyright","label":"Copyright"}]}}